Women Home > Latisse Warnings and Precautions

Before taking Latisse, tell your healthcare provider about any medical conditions you have, such as glaucoma, an inflammatory eye condition, or any allergies. Also, this medication can cause drug interactions, so it's important that your healthcare provider is aware of all other medicines you are taking (including nonprescription products). Other precautions and warnings with Latisse apply to women who are pregnant or breastfeeding.

What Should I Tell My Healthcare Provider?

Prior to using Latisse® (bimatoprost ophthalmic solution), tell your healthcare provider if you have:
  • Glaucoma
  • An inflammatory eye condition, such as iritis or uveitis
  • A missing lens of the eye (a condition known as aphakia)
  • An artificial lens of the eye (such as if you have had cataract surgery)
  • Any allergies, including to foods, dyes, or preservatives.
Also, let your healthcare provider know if you are:
  • Pregnant or thinking of becoming pregnant
  • Breastfeeding.
Make sure to tell your healthcare provider about any other medications you are taking, including prescription and nonprescription medicines, vitamins, and herbal supplements.

Specific Precautions and Warnings With Latisse

Some warnings and precautions to be aware of prior to using Latisse include the following:
  • Latisse can lower the pressure within the eye, which is why it is used under a different name (Lumigan®) to treat high eye pressure. The changes in eye pressure with Latisse are not significant enough to be a concern for most people.
Interestingly, however, combining Latisse with Lumigan (or other similar glaucoma medications) can actually make Lumigan less effective at reducing eye pressure. For this reason, people who take Lumigan or other similar glaucoma medications should not use Latisse (see Latisse Drug Interactions for more information).
  • When applied directly to the eye, the active ingredient in Latisse is known to cause permanent darkening of the iris (the colored part of the eye) to a brownish color in people who have light-colored eyes (such as blue eyes). This problem has been reported with Lumigan, a glaucoma medication that contains the same active ingredient as Latisse. However, because Lumigan is used directly in the eye and Latisse is not, this may not be a problem with Latisse.
  • This product can cause skin darkening around the eyes, particularly if care is not taken to make sure the surrounding skin is not exposed to it. This is usually reversible once the medication is stopped.
  • Latisse can cause hair growth in undesired places if the solution repeatedly comes into contact with the skin. Make sure to apply the medication carefully and to blot away any excess. Also, do not apply it to the lower lids, as doing so may increase the risk of undesired hair growth.
  • Latisse can worsen inflammation within the eye and may not be a good choice for people with inflammatory eye conditions.
  • There have been reports of macular edema (swelling of the macula of the eye) in some people who took Lumigan (the eye drop formulation used to treat glaucoma). Make sure to let your healthcare provider know if you have any vision changes, as they may be a sign of macular edema. People missing an eye lens or those with artificial lenses within the eye (such as people who have had cataract surgery) may be at a higher risk for this complication.
  • Make sure to avoid contaminating the tip of the bottle. Do not touch it to any surface other than the sterile applicators. Each applicator should be used only once, on one eye only, after which you must discard it.
  • You must remove your contact lenses before applying Latisse. You may reinsert them 15 minutes after applying the medication.
  • Latisse is considered a pregnancy Category C medication. This means that it might not be safe for use during pregnancy, although the full risks are not currently known (see Latisse and Pregnancy).
  • It is unknown if Latisse passes through breast milk. Therefore, if you are breastfeeding or plan to start, discuss this with your healthcare provider prior to taking the drug (see Latisse and Breastfeeding).
Written by/reviewed by:
Last reviewed by: Kristi Monson, PharmD;
Last updated/reviewed:
List of references (click here):
Other Articles in This eMedTV Presentation




Related Channels

eMedTV Links
Copyright © 2006-2020 Clinaero, Inc.

eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.

This site complies with the HONcode standard for trustworthy health information:
verify here.